Lexicon Presents Positive Outcome In IBS Patients Treated With LX1031 And Data Supporting Mechanism Of Action
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana…
This entry was posted on Friday, May 7th, 2010 at 1:00 am and is filed under Irritable Bowel Syndrome. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.